QLSF Biotherapeutics is focused on developing next-generation antibody-based therapeutics aimed at addressing challenging targets in cancer treatment. The company employs a rational design approach to create modular and customizable molecules that target both the adaptive and innate immune systems, enhancing anti-tumor activity through complementary mechanisms. Their pipeline includes innovative candidates such as QL401, a bispecific antibody targeting PD-L1 and CD47, and QL301, which engages PD-L1 and 4-1BB to stimulate T cells in a controlled manner. These candidates are designed to improve therapeutic windows and minimize adverse effects, such as anemia, while promoting robust immune responses against tumors.

The company’s technology also includes advanced T cell engagers that enhance tumor targeting specificity and reduce systemic toxicity compared to traditional bispecific antibodies. Their T cell engagers, such as QL325 and QL335, utilize avidity-driven binding to improve tumor selectivity and provide co-stimulatory signals to invigorate T cell responses. This innovative approach aims to overcome the limitations of existing therapies by ensuring that T cells are effectively activated in the tumor microenvironment, thereby enhancing the overall efficacy of cancer treatments. QLSF's commitment to leveraging interdisciplinary expertise and a diversified oncology portfolio positions it as a promising player in the immuno-oncology landscape.

United States

QLSF Biotherapeutics is an innovative immuno-oncology startup company in South San Francisco. Our research and development are focused on a diversified oncology portfolio, with strong financial and clinical development support from a leading pharmaceutical company.

QLSF Biotherapeutics

Company Details